The overall response rate was 35% in the sacituzumab govitecan arm and 5% in the chemotherapy arm.
Key treatment-related adverse events of grade 3 or higher occurred more often in patients who received sacituzumab govitecan than patients who received chemotherapy: neutropenia (51% vs.
33%), leukopenia (10% vs.
5%), diarrhea (10% vs.
<1%), anemia (8% vs.
5%), and febrile neutropenia (6% vs.
2%).
Patients with TNBC and a germlineBRCApathogenic variant are eligible for PARP inhibitor therapy.
For more information, see theGermlineBRCA-Mutated Metastatic Breast Cancersection.
Chemotherapy may be appropriate for patients with TNBC.